Magnetic Resonance Imaging — Detailed Body Scans

Magnetic resonance imaging works by temporarily aligning the hydrogen atoms (protons) in human tissues using a strong static magnetic field. Radiofrequency pulses are then transmitted into the patient, deflecting these protons from their equilibrium state. When the pulses stop, protons relax back to their baseline alignment, emitting faint radio signals detected by external receiver coils.

Different biological tissues release these radiofrequency signals at distinct rates, which computer systems translate into multi-planar anatomical images. Clinicians frequently administer intravenous gadolinium-based contrast agents during examinations. These agents alter local relaxation times, highlighting areas of hypervascularity or blood-brain barrier disruption that are typical of malignant growths.

MRI is indispensable in oncological care due to its superior soft-tissue contrast resolution. It allows clinicians to distinguish malignant tumours from benign structures, evaluate depth of local invasion, and inspect delicate structures such as the spinal cord, brain, and nerves. Furthermore, MRI precisely evaluates tumour responses to pre-operative therapies, guides needle biopsies, and assists radiation oncologists in sculpting accurate treatment fields while sparing adjacent healthy organs.

While MRI is an imaging instrument rather than a laboratory test, it works alongside tissue biomarkers. Contrast-enhanced scans track gadolinium perfusion kinetics, while functional sequences like Diffusion-Weighted Imaging (DWI) assess cellular density. Dynamic contrast-enhanced (DCE) MRI can indicate tumour angiogenesis, which often correlates with molecular markers like VEGF or hormonal receptor status in tumours.

MRI is the preferred imaging modality for brain tumours and spinal cord neoplasms. It is routinely used to stage rectal cancer by assessing the mesorectal fascia, and plays an integral role in evaluating prostate cancer via multiparametric MRI (mpMRI). It is equally essential for characterizing soft-tissue and bone sarcomas, evaluating hepatic lesions, assessing head and neck tumours, and serving as a high-sensitivity screening tool for women at high genetic risk of breast cancer.

MRI findings directly govern whether a tumour is deemed surgically resectable with clear anatomical margins. In modern radiotherapy, MRI data are registered with CT plans to delineate gross tumour volume with millimetre accuracy. For patients undergoing neoadjuvant chemotherapy or immunotherapy, interval MRI scans indicate whether tumours are regressing, guiding the timing and invasiveness of subsequent operations.